bluebird bio Announces Proposed Public Offering of Common Stock Read more about bluebird bio Announces Proposed Public Offering of Common Stock
bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress Read more about bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress
Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20 Read more about Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20
Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma Read more about Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement Read more about bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement
bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results Read more about bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results
bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program Read more about bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program
BofA Securities Health Care Conference 2020 Read more about BofA Securities Health Care Conference 2020